EG142A

EG142A is a preclinical-stage gene therapy being developed by EG 427 for the treatment of an undisclosed neuromuscular disease. It is built upon a proprietary platform that utilizes non-replicative Herpes Simplex Virus type 1 (HSV-1) vectors to deliver DNA medicines. This platform leverages the natural neurotropism of HSV-1 to target the peripheral nervous system efficiently. The non-replicative nature of the vector ensures safety by preventing viral spread, while its large cargo capacity allows for the delivery of complex genetic sequences. The therapy is designed to remain episomal within the neuronal nucleus, potentially providing long-term gene expression without the risks associated with genomic integration.